Trial Profile
Clinical study of Apapinib Combination with EGFR-TKIs in Patients with Non-small cell lung cancer(NSCLC) who Developed Acpuired Resistance
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Icotinib (Primary) ; Rivoceranib (Primary) ; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 05 Jun 2018 Results (n=19) assessing efficacy and safety of apatinib combined with EGFR-TKIs (including erlotinib, gefitinib and icotinib) in patients with advanced non-small cell lung cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jul 2017 New trial record